Compare NXST & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | BLTE |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2002 | 2021 |
| Metric | NXST | BLTE |
|---|---|---|
| Price | $186.48 | $156.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $263.75 | $198.00 |
| AVG Volume (30 Days) | ★ 378.4K | 151.0K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.09 | N/A |
| Revenue | ★ $4,949,000,000.00 | N/A |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | N/A | $492.11 |
| P/E Ratio | $36.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $154.47 | $60.00 |
| 52 Week High | $254.30 | $200.00 |
| Indicator | NXST | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 55.25 |
| Support Level | $177.36 | $146.18 |
| Resistance Level | $191.30 | $160.48 |
| Average True Range (ATR) | 6.10 | 6.37 |
| MACD | 0.95 | 0.40 |
| Stochastic Oscillator | 72.64 | 67.93 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Assuming its merger with Tegna is affirmed Nexstar's station total would exceed 259 and reach 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.